Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Return on Equity (2018 - 2025)

Denali Therapeutics (DNLI) has disclosed Return on Equity for 8 consecutive years, with 0.51% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Equity fell 18.0% to 0.51% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.51%, a 18.0% decrease, with the full-year FY2024 number at 0.37%, down 23.0% from a year prior.
  • Return on Equity was 0.51% for Q3 2025 at Denali Therapeutics, down from 0.45% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.05% in Q2 2021 to a low of 0.51% in Q3 2025.
  • A 5-year average of 0.25% and a median of 0.31% in 2022 define the central range for Return on Equity.
  • Peak YoY movement for Return on Equity: soared 51bps in 2021, then plummeted -39bps in 2022.
  • Denali Therapeutics' Return on Equity stood at 0.29% in 2021, then decreased by -21bps to 0.36% in 2022, then soared by 59bps to 0.15% in 2023, then crashed by -125bps to 0.33% in 2024, then crashed by -54bps to 0.51% in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Return on Equity are 0.51% (Q3 2025), 0.45% (Q2 2025), and 0.39% (Q1 2025).